Sergio Schwartzman
Rheumatology · New York, NYNPI 1841225521
Payments from drug & device makers
Across 2,340 payments — averaging $1050.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$601K
- UCB, Inc.$490K
- Lilly USA, LLC$489K
- Johnson & Johnson$328K
- Janssen Scientific Affairs, LLC$155K
- Pfizer$148K
- plus $249K from 21 others
Across 12 payments — averaging $1655.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$13K
- AbbVie$3K
- UCB, Inc.$3K
- Sanofi-aventis U.S. LLC$1K
What the payments were for
- Consulting fees$469,04719%
- Speaking & faculty fees$1,606,30465%
- Travel & lodging$348,76214%
- Food & beverage$35,0251%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 494 | $601,166 |
| UCB, Inc. | 552 | $489,562 |
| Lilly USA, LLC | 553 | $488,588 |
| Johnson & Johnson(2 entities) | 266 | $327,964 |
| Janssen Scientific Affairs, LLC | 111 | $155,362 |
| Pfizer | 164 | $148,021 |
| Novartis | 90 | $121,341 |
| Novartis Pharma AG | 28 | $52,984 |
| Jubilant Draximage Inc. | 3 | $26,500 |
| Regeneron Healthcare Solutions, Inc. | 16 | $19,114 |
| Gilead | 10 | $7,618 |
| Eli Lilly | 3 | $5,311 |
| Genentech USA, Inc. | 6 | $4,941 |
| Biogen | 4 | $3,742 |
| Amgen(2 entities) | 21 | $2,483 |
| Mallinckrodt Hospital Products Inc. | 1 | $1,600 |
| Aurinia Pharma U.S., Inc. | 1 | $1,500 |
| Sanofi | 3 | $1,145 |
| E.r. Squibb & Sons, L.L.C. | 3 | $75 |
| GSK | 3 | $64 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $57 |
| Pfizer Pharmaceuticals Korea Limited | 1 | $36 |
| Genmab U.S., Inc. | 1 | $33 |
| AstraZeneca | 1 | $26 |
| Tonix Medicines, Inc. | 1 | $18 |
| Oxford Immunotec USA Inc | 1 | $16 |
| Incyte Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$413,706
- Tremfya$387,335
- TALTZ$350,922
- Rinvoq$331,927
- Cimzia$213,504
- Skyrizi$176,621
- Bimzelx$167,530
- XELJANZ$144,644
- STELARA$133,516
- COSENTYX$119,035
- Humira$82,157
- AIN457F_COSENTYX_IMMUNOLOGY$41,484
- KEVZARA$20,136
- REMICADE$16,538
- COSENTYX_COSENTYX_DERMATOLOGY$10,250
- TOFIDENCE$3,679
- ZEPBOUND$3,500
- KRYSTEXXA$2,025
- OLUMIANT$1,800
- ACTHAR$1,600
How this compares
$2,459,284 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 39 | $267,193 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $227,583 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 23 | $178,350 |
| NucalaMepolizumab | 13 | $169,314 |
| Orencia ClickjectAbatacept | 16 | $146,993 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $126,302 |
| KineretAnakinra | 11 | $61,313 |
| KevzaraSarilumab | 13 | $55,331 |
| Methylprednisolone | 54 | $1,631 |
| Febuxostat | 14 | $1,398 |
| Mycophenolate Mofetil | 19 | $803 |
| Hydroxychloroquine Sulfate | 18 | $657 |
| Prednisone | 41 | $555 |
| MethotrexateMethotrexate Sodium | 23 | $409 |
| Meloxicam | 23 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala | $64 | $169,31413 claims |
| UCB, Inc.Cimzia (2 Pack) | $489,562 | $126,30215 claims |
| SanofiKevzara | $1,145 | $55,33113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 541 rheumatology providers in New York.
Other rheumatology in New York
- Amit SaxenaNew York$6.7M
- Robert SpieraNew York$4.3M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Allan GibofskyNew York$1.9M
- Laura Geraldino PardillaNew York$1.7M
- Joan BathonNew York$1.6M
- Michael PillingerNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.